Home › Funds › Atle Fund Management AB › NAMS

Atle Fund Management AB position in NAMS

NEWAMSTERDAM PHARMA CO NV · Health Care

Atle Fund Management AB reported holding 303,824 shares of NAMS (NEWAMSTERDAM PHARMA CO NV) in its Q3 2026 13F filing — a position valued at US$7.4M, representing 1.98% of its reported portfolio and ranking #20 among its reported holdings. Atle Fund Management AB has disclosed NAMS holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)303.82K sh
Reported value held$7.39M
Portfolio Weight1.98%
First reportedQ1 2024
Last changeAdd
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Atle Fund Management AB's NAMS position evolved

Atle Fund Management AB first disclosed a stake in NAMS in Q1 2024 at 22,394 shares (US$530K). The position peaked in Q2 2026 at 248,848 shares, worth US$8.4M. Across 11 filings, Atle Fund Management AB increased the stake 7 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 303,824 shares valued at US$7.4M — an increase of 54,976 shares quarter over quarter.. Notable position changes include a 238% increase in Q2 2024 (shares fell 10% over the following quarter), a 83% increase in Q3 2024 (shares rose 45% over the following quarter), a 163% increase in Q2 2026 (shares fell 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 22.39K $529.62K New
Q2 2024 75.79K $1.46M Add
Q3 2024 138.98K $2.31M Add
Q4 2024 138.98K $3.56M Hold
Q1 2025 107.78K $2.21M Reduce
Q2 2025 157.22K $2.85M Add
Q3 2025 193.62K $584.61K Add
Q4 2025 197.04K $6.91M Add
Q1 2026 94.80K $5.51M Reduce
Q2 2026 248.85K $8.43M Add
Q3 2026 303.82K $7.39M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA CO NV) is a Health Care company. 44 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has Atle Fund Management AB held NAMS?

Atle Fund Management AB has disclosed NAMS holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is Atle Fund Management AB's current position in NAMS?

As of Q3 2026, Atle Fund Management AB holds 303.82K shares of NAMS (NEWAMSTERDAM PHARMA CO NV), valued at $7.39M, representing 1.98% of its reported portfolio and ranking #20.

Has Atle Fund Management AB been buying or selling NAMS?

In the latest 13F filing (Q3 2026), Atle Fund Management AB increased its position in NAMS. The position peaked in Q2 2026 at 248.85K shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.